Clinical trial results:
A three year extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in subjects with active psoriatic arthritis

Summary

EudraCT number	2013-001241-13
Trial protocol	IT GB CZ DE PL BG BE SK
Global end of trial date	11 January 2018

Results information

Result version number	v1 (current)
This version publication date	26 January 2019
First version publication date	26 January 2019

Trial information

Trial identification

Sponsor protocol code	CAIN457F2306E1

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01892436
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Novartis Pharma AG
Sponsor organisation address	CH-4002, Basel, Switzerland,
Public contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com
Scientific contact	Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, novartis.email@novartis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	11 January 2018
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	11 January 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The primary objective was to evaluate the long term efficacy of secukinumab with respect to ACR20, ACR50 and ACR70 response over time up to Week 260 in patients with active PsA who completed the Phase 3 core study CAIN457F2306

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 September 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 27
Country: Number of subjects enrolled	Australia: 21
Country: Number of subjects enrolled	Belgium: 6
Country: Number of subjects enrolled	Brazil: 16
Country: Number of subjects enrolled	Bulgaria: 12
Country: Number of subjects enrolled	Canada: 24
Country: Number of subjects enrolled	Czech Republic: 44
Country: Number of subjects enrolled	Germany: 48
Country: Number of subjects enrolled	Israel: 35
Country: Number of subjects enrolled	Italy: 22
Country: Number of subjects enrolled	Philippines: 66
Country: Number of subjects enrolled	Poland: 23
Country: Number of subjects enrolled	Romania: 4
Country: Number of subjects enrolled	Russian Federation: 40
Country: Number of subjects enrolled	Singapore: 16
Country: Number of subjects enrolled	Slovakia: 2
Country: Number of subjects enrolled	Thailand: 30
Country: Number of subjects enrolled	United Kingdom: 37
Country: Number of subjects enrolled	United States: 133

Worldwide total number of subjects	606
EEA total number of subjects	198

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	552
From 65 to 84 years	54
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The extension FAS (N=457) comprised all patients enrolled in the extension with at least 1 post baseline efficacy assessment during the extension study. 3 patients signed the ICF but had no efficacy assessments during the extension study and were not included in extension FAS.

Pre-assignment

Screening details:

Of the 457 patients in the extension FAS, 380 (83.2%) completed 260 weeks of treatment (84.4% in the secukinumab 10 mg/kg-75 mg group, 82.0% in the secukinumab 10 mg/kg-150 mg group, 85.1% in the placebo-secukinumab 75 mg group and 81.3% in the placebo-secukinumab 150 mg group)

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Data analyst

Arms

Are arms mutually exclusive?	Yes
Arm title	Secukinumab 75mg

Arm description:

Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator

Arm type	Experimental
Investigational medicinal product name	secukinumab
Investigational medicinal product code	AIN457F
Other name	
Pharmaceutical forms	Solution for infusion in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

75 mg

Arm title	Secukinumab 150mg

Arm description:

Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator

Arm type	Experimental
Investigational medicinal product name	secukinumab
Investigational medicinal product code	AIN457F
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

150 MG

Arm title	Placebo - AIN457A 75mg

Arm description:

Placebo (for maintaining the blind till Week 152): Placebo to secukinumab .05 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also

received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

75 mg

Arm title	Placebo - AIN457 150mg

Arm description:

Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator

Arm type	Placebo
Investigational medicinal product name	placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for infusion in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

150 mg

Number of subjects in period 1[1]	Secukinumab 75mg	Secukinumab 150mg	Placebo - AIN457A 75mg
Started	147	161	74
Completed	124	132	63
Not completed	23	29	11
Adverse event, serious fatal	1	1	-
Consent withdrawn by subject	8	15	4
Physician decision	2	1	-
non-compliance with treatment	1	-	-
Technical problems	2	1	1
Adverse event, non-fatal	7	6	2
Pregnancy	-	2	1
Lost to follow-up	1	1	1
Lack of efficacy	1	2	2

Number of subjects in period 1[1]	Placebo - AIN457 150mg
Started	75
Completed	61
Not completed	14

Adverse event, serious fatal	-
Consent withdrawn by subject	4
Physician decision	1
non-compliance with treatment	-
Technical problems	1
Adverse event, non-fatal	3
Pregnancy	-
Lost to follow-up	3
Lack of efficacy	2

Notes:

[1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
Justification: Of the 457 patients in the extension FAS, 380 (83.2%) completed 260 weeks of treatment (84.4% in the secukinumab 10 mg/kg-75 mg group, 82.0% in the secukinumab 10 mg/kg-150 mg group, 85.1% in the placebo-secukinumab 75 mg group and 81.3% in the placebo-secukinumab 150 mg group)

Baseline characteristics

Reporting groups	
Reporting group title	Secukinumab 75mg
Reporting group description:	
Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator	
Reporting group title	Secukinumab 150mg
Reporting group description:	
Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator	
Reporting group title	Placebo - AIN457A 75mg
Reporting group description:	
Placebo (for maintaining the blind till Week 152): Placebo to secukinumab .05 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator	
Reporting group title	Placebo - AIN457 150mg
Reporting group description:	
Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator	

Reporting group values	Secukinumab 75mg	Secukinumab 150mg	Placebo - AIN457A 75mg
Number of subjects	147	161	74
Age, Customized Units: Subjects			
18y - <65 y	132	145	72
>=65 y -<85	15	16	2
Age continuous Units: years			
arithmetic mean	48.9	49.5	47.4
standard deviation	± 11.78	± 11.67	± 10.64
Sex: Female, Male Units: Subjects			
Female	81	83	40
Male	66	78	34
Race/Ethnicity, Customized Units: Subjects			
White	118	130	51
Black or African American	1	1	0
Asian	27	29	23
Other	1	1	0

Reporting group values	Placebo - AIN457 150mg	Total	
Number of subjects	75	457	

Age, Customized Units: Subjects			
18y - <65 y	71	420	
>=65 y -<85	4	37	
Age continuous Units: years			
arithmetic mean	49.0		
standard deviation	± 11.42	-	
Sex: Female, Male Units: Subjects			
Female	38	242	
Male	37	215	
Race/Ethnicity, Customized Units: Subjects			
White	58	357	
Black or African American	0	2	
Asian	16	95	
Other	1	3	

End points

End points reporting groups

Reporting group title	Secukinumab 75mg
Reporting group description:	
Subjects continued to receive secukinumab 75mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator	
Reporting group title	Secukinumab 150mg
Reporting group description:	
Subjects continued to receive secukinumab 150mg in PFS (same dose as that was received in core study CAIN457F2306) every 4 weeks up to Week 256. From Week 156, patients may have been escalated to 300 mg as judged appropriate by the investigator	
Reporting group title	Placebo - AIN457A 75mg
Reporting group description:	
Placebo (for maintaining the blind till Week 152): Placebo to secukinumab .05 mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 75mg. Participants also received secukinumab 75mg from week 16/24. Patients may have been escalated to 150 mg or 300 mg as judged appropriate by investigator	
Reporting group title	Placebo - AIN457 150mg
Reporting group description:	
Placebo (for maintaining the blind till Week 152): Placebo to secukinumab 0.5mL solution for injection was provided in PFS for s.c. administration (a single use pre-filled 1mL long glass syringe). It contained a mixture of inactive excipients, matching the composition of secukinumab 150 mg. Participants also received secukinumab 150 mg from week 16/24. patients may have been escalated to 300mg or 300 mg as judged appropriate by investigator	

Primary: Proportion of subject who reached (American College of Rheumatology score of 20) ACR20

End point title	Proportion of subject who reached (American College of Rheumatology score of 20) ACR20[1]
End point description:	
Proportion of subjects with a positive clinical response to treatment (individual improvement) in disease activity according to ACR20 criteria if he/she has at least 20% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures: - Patient's assessment of Psoriatic Arthritis (PsA) pain - Patient's global assessment of disease activity - Physician's global assessment of disease activity - Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score) - Acute phase reactant (hsCRP or ESR)	
End point type	Primary
End point timeframe:	
weeks 116, 128, 140, 156, 180, 208, 232 and 260	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: NO STATISTICAL ANALYSIS WAS PLANNED

End point values	Secukinumab 75mg	Secukinumab 150mg	Placebo - AIN457A 75mg	Placebo - AIN457 150mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	147	161	74	75
Units: percentage of participants				
number (confidence interval 95%)				
week 116	71.3 (63.1 to 78.4)	73.9 (66.0 to 80.5)	73.2 (61.2 to 82.7)	73.6 (61.7 to 83.0)

week 128	69.7 (61.4 to 77.0)	72.9 (65.1 to 79.6)	76.8 (64.8 to 85.8)	74.6 (62.7 to 83.9)
week 140	69.8 (61.3 to 77.1)	71.1 (63.1 to 78.0)	79.2 (67.7 to 87.5)	69.4 (57.3 to 79.5)
week 156	64.3 (55.8 to 72.0)	76.1 (68.5 to 82.4)	75.3 (63.6 to 84.4)	67.6 (55.6 to 77.7)
week 180	73.0 (64.6 to 80.0)	72.5 (64.1 to 79.6)	74.6 (62.3 to 84.1)	67.7 (54.8 to 78.5)
week 208	72.8 (64.4 to 79.9)	66.9 (58.5 to 74.3)	75.0 (62.8 to 84.4)	68.2 (55.4 to 78.8)
week 232	79.5 (71.3 to 86.0)	69.5 (60.7 to 77.0)	83.3 (71.7 to 91.0)	80.3 (67.8 to 89.0)
week 260	77.2 (68.7 to 83.9)	67.9 (59.1 to 75.7)	78.8 (66.7 to 87.5)	77.4 (64.7 to 86.7)

Statistical analyses

No statistical analyses for this end point

Primary: Proportion of subjects who reached ACR50

End point title	Proportion of subjects who reached ACR50[2]

End point description:

Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR50 criteria if he/she has at least 50% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures: - Patient's assessment of PsA pain - Patient's global assessment of disease activity - Physician's global assessment of disease activity - Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score) - Acute phase reactant (hsCRP or ESR)

End point type	Primary

End point timeframe:

weeks 116, 128, 140, 156, 180, 208, 232 and 260

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: NO STATISTICAL ANALYSIS WAS PLANNED

End point values	Secukinumab 75mg	Secukinumab 150mg	Placebo - AIN457A 75mg	Placebo - AIN457 150mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	147	161	74	75
Units: percentage of participants				
number (confidence interval 95%)				
week 116	43.4 (35.2 to 51.9)	51.0 (42.8 to 59.1)	49.3 (37.3 to 61.3)	47.2 (35.5 to 59.3)
week 128	43.7 (35.4 to 52.2)	52.9 (44.8 to 60.9)	56.5 (44.1 to 68.2)	53.5 (41.4 to 65.3)
week 140	41.7 (33.5 to 50.4)	48.7 (40.5 to 56.9)	51.4 (39.4 to 63.2)	44.4 (32.9 to 56.6)
week 156	39.2 (31.2 to 47.7)	56.1 (47.9 to 64.0)	52.1 (40.1 to 63.8)	47.3 (35.7 to 59.2)
week 180	43.1 (34.7 to 51.8)	45.7 (37.2 to 54.3)	52.2 (39.8 to 64.4)	50.8 (38.2 to 63.3)
week 208	44.9 (36.4 to 53.6)	46.9 (38.6 to 55.3)	52.9 (40.5 to 65.0)	53.0 (40.4 to 65.3)
week 232	49.6 (40.7 to 58.6)	53.4 (44.5 to 62.1)	53.0 (40.4 to 65.3)	50.8 (37.8 to 63.7)

week 260	51.2 (42.2 to 60.1)	52.7 (43.8 to 61.4)	60.6 (47.8 to 72.2)	50.0 (37.2 to 62.8)

Statistical analyses

No statistical analyses for this end point

Primary: Proportion of subjects who reached ACR70

End point title	Proportion of subjects who reached ACR70[3]

End point description:

Proportion of subjects that have a positive clinical response to treatment (individual improvement) in disease activity according to ACR70 criteria if he/she has at least 70% improvement in 1. Tender 68-joint count 2. Swollen 66-joint count and 3. At least 3 of the following 5 measures:- Patient's assessment of PsA pain - Patient's global assessment of disease activity - Physician's global assessment of disease activity - Subject self-assessed disability (Health-Assessment Questionnaire [HAQ-DI] score) - Acute phase reactant (hsCRP or ESR)

End point type	Primary

End point timeframe:

weeks 116, 128, 140, 156, 180, 208, 232 and 260

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: NO STATISTICAL ANALYSIS WAS PLANNED

End point values	Secukinumab 75mg	Secukinumab 150mg	Placebo - AIN457A 75mg	Placebo - AIN457 150mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	147	161	74	75
Units: percentage of participants				
number (confidence interval 95%)				
week 116	23.8 (17.2 to 31.8)	30.1 (23.1 to 38.1)	28.2 (18.4 to 40.3)	29.2 (19.3 to 41.2)
week 128	24.6 (18.0 to 32.7)	31.0 (23.9 to 39.0)	34.8 (24.0 to 47.3)	23.9 (14.9 to 35.8)
week 140	27.3 (20.3 to 35.7)	28.3 (21.4 to 36.3)	33.3 (22.9 to 45.5)	27.8 (18.2 to 39.8)
week 156	25.9 (19.1 to 34.0)	32.9 (25.7 to 41.0)	26.0 (16.8 to 37.8)	27.0 (17.7 to 38.8)
week 180	27.0 (20.0 to 35.4)	31.2 (23.7 to 39.7)	31.3 (20.9 to 44.0)	27.7 (17.7 to 40.4)
week 208	25.7 (18.8 to 34.1)	31.0 (23.8 to 39.3)	32.4 (21.8 to 44.9)	28.8 (18.6 to 41.4)
week 232	35.4 (27.3 to 44.5)	32.1 (24.3 to 40.9)	37.9 (26.5 to 50.7)	34.4 (23.0 to 47.8)
week 260	33.9 (25.9 to 42.9)	37.4 (29.2 to 46.3)	37.9 (26.5 to 50.7)	33.9 (22.6 to 47.1)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

End point title	Change from baseline in Health Assessment Questionnaire Disability Index (HAQ-DI)

End point description:

Changes from baseline in score of the disability assessment component of the HAQ (Health Assessment Questionnaire - Disability Index). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.

End point type	Secondary

End point timeframe:

weeks 116, 128, 140, 156, 180, 208, 232 and 260

End point values	Secukinumab 75mg	Secukinumab 150mg	Placebo - AIN457A 75mg	Placebo - AIN457 150mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	147	161	74	75
Units: change in scores				
arithmetic mean (standard deviation)				
week 116	-0.4537 (± 0.60617)	-0.4592 (± 0.56155)	-0.5642 (± 0.56722)	-0.4115 (± 0.66721)
week 128	-0.4171 (± 0.61192)	-0.4619 (± 0.55835)	-0.5143 (± 0.55599)	-0.3750 (± 0.69661)
week 140	-0.4448 (± 0.61406)	-0.4713 (± 0.58791)	-0.4635 (± 0.56037)	-0.3507 (± 0.69221)
week 156	-0.4236 (± 0.61896)	-0.4266 (± 0.57491)	-0.5068 (± 0.62548)	-0.3159 (± 0.73507)
week 180	-0.4617 (± 0.61472)	-0.4305 (± 0.59901)	-0.5698 (± 0.65258)	-0.3538 (± 0.71246)
week 208	-0.4463 (± 0.57130)	-0.3857 (± 0.59304)	-0.5531 (± 0.62622)	-0.3447 (± 0.74745)
week 232	-0.4710 (± 0.60931)	-0.4122 (± 0.60461)	-0.5777 (± 0.66930)	-0.3952 (± 0.72115)
week 260	-0.4821 (± 0.61170)	-0.4036 (± 0.58334)	-0.5038 (± 0.61039)	-0.3730 (± 0.71306)

Statistical analyses

No statistical analyses for this end point

Secondary: Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Disability Index (HAQ-DI)

End point title	Minimal Clinically Important Difference (MCID) in Health Assessment Questionnaire Disability Index (HAQ-DI)

End point description:

Percentage of subjects with improvements from baseline in HAQ-DI meeting or exceeding minimal clinically important difference (MCID=0.3). The HAQ-DI, assesses a subject's level of functional ability and includes questions of fine movements of the upper extremity, locomotor activities of the lower extremity, and activities that involve both upper and lower extremities.

End point type	Secondary

End point timeframe:

weeks 116, 128, 140, 156, 180, 208, 232 and 260

End point values	Secukinumab 75mg	Secukinumab 150mg	Placebo - AIN457A 75mg	Placebo - AIN457 150mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	147	161	74	75
Units: percentage of participants				
number (confidence interval 95%)				
week 116	53.1 (44.6 to 61.5)	52.3 (44.1 to 60.4)	63.9 (51.7 to 74.6)	50.0 (38.1 to 61.9)
week 128	52.8 (44.3 to 61.2)	51.9 (43.8 to 60.0)	57.1 (44.8 to 68.7)	54.9 (42.7 to 66.6)
week 140	55.4 (46.7 to 63.7)	52.3 (44.1 to 60.4)	56.9 (44.8 to 68.4)	48.6 (36.8 to 60.6)
week 156	52.8 (44.3 to 61.1)	52.3 (44.1 to 60.3)	60.8 (48.7 to 71.7)	44.6 (33.2 to 56.6)
week 180	56.9 (48.2 to 65.3)	51.5 (42.8 to 60.1)	61.2 (48.5 to 72.6)	47.7 (35.3 to 60.4)
week 208	53.3 (44.6 to 61.9)	50.0 (41.6 to 58.4)	59.4 (46.9 to 70.9)	48.5 (36.1 to 61.0)
week 232	55.2 (46.1 to 64.0)	48.9 (40.1 to 57.7)	59.1 (46.3 to 70.8)	52.5 (39.4 to 65.2)
week 260	55.6 (46.5 to 64.3)	48.9 (40.1 to 57.7)	59.1 (46.3 to 70.8)	53.2 (40.2 to 65.8)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline in Disease Activity Score-CRP (DAS28)

End point title	Change from baseline in Disease Activity Score-CRP (DAS28)

End point description:

Changes in DAS28 (utilizing hsCRP) from baseline to over entire study duration up to Month 60. The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission. This measure represents change in scores - not the actual scores.

End point type	Secondary

End point timeframe:

weeks 116, 128, 140, 156, 180, 208, 232 and 260

End point values	Secukinumab 75mg	Secukinumab 150mg	Placebo - AIN457A 75mg	Placebo - AIN457 150mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	147	161	74	75
Units: change in scores				
arithmetic mean (standard deviation)				
week 116	-2.044 (± 1.3382)	-1.904 (± 1.3165)	-2.282 (± 1.2732)	-1.853 (± 1.2737)

week 128	-2.013 (± 1.3446)	-1.962 (± 1.2900)	-2.333 (± 1.2815)	-2.031 (± 1.3290)
week 140	-2.074 (± 1.3224)	-1.912 (± 1.2246)	-2.412 (± 1.3059)	-1.830 (± 1.3136)
week 156	-1.844 (± 1.4923)	-1.942 (± 1.3195)	-2.109 (± 1.3188)	-1.743 (± 1.3630)
week 180	-2.058 (± 1.3760)	-1.937 (± 1.2674)	-2.327 (± 1.2339)	-1.867 (± 1.4590)
week 208	-2.042 (± 1.2907)	-1.767 (± 1.4574)	-2.344 (± 1.3351)	-1.862 (± 1.4708)
week 232	-2.225 (± 1.2570)	-2.046 (± 1.2590)	-2.611 (± 1.3247)	-2.286 (± 1.2102)
week 260	-2.112 (± 1.2664)	-2.074 (± 1.3146)	-2.506 (± 1.3774)	-2.099 (± 1.2466)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of subjects achieving low disease activity

End point title	Percentage of subjects achieving low disease activity

End point description:

Percentage of subjects achieving low disease activity (DAS28 ≤ 3.2). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission

End point type	Secondary

End point timeframe:

weeks 116, 128, 140, 156, 180, 208, 232 and 260

End point values	Secukinumab 75mg	Secukinumab 150mg	Placebo - AIN457A 75mg	Placebo - AIN457 150mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	147	161	74	75
Units: percentage of participants				
number (confidence interval 95%)				
week 116	70.3 (62.1 to 77.5)	64.7 (56.5 to 72.1)	70.4 (58.2 to 80.4)	63.9 (51.7 to 74.6)
week 128	69.5 (61.1 to 76.8)	69.9 (61.9 to 76.8)	75.4 (63.3 to 84.6)	68.6 (56.2 to 78.9)
week 140	72.9 (64.6 to 79.9)	66.0 (57.8 to 73.4)	75.0 (63.2 to 84.1)	65.3 (53.1 to 75.9)
week 156	63.4 (54.8 to 71.2)	67.9 (59.9 to 75.1)	61.6 (49.5 to 72.6)	58.9 (46.8 to 70.1)
week 180	71.2 (62.8 to 78.4)	70.1 (61.6 to 77.4)	65.7 (53.0 to 76.6)	68.8 (55.8 to 79.4)
week 208	71.7 (63.3 to 78.9)	65.8 (57.4 to 73.3)	67.2 (54.5 to 77.9)	71.2 (58.6 to 81.4)
week 232	75.2 (66.7 to 82.2)	73.5 (65.0 to 80.6)	79.4 (67.0 to 88.1)	84.7 (72.5 to 92.4)
week 260	74.4 (65.8 to 81.5)	75.0 (66.6 to 81.9)	76.9 (64.5 to 86.1)	77.4 (64.7 to 86.7)

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of subjects achieving disease remission (DAS28<2.6)

End point title	Percentage of subjects achieving disease remission (DAS28<2.6)

End point description:

Percentage of subjects achieving disease remission (DAS28<2.6). The DAS28 is a measure of disease activity in PsA based on Swollen and Tender Joint Counts (out of a total of 28), hsCRP and the Patient's Global Assessment of Disease Activity. A DAS28 score greater than 5.1 implies active disease, equal to or less than 3.2 low disease activity, and less than 2.6 remission

End point type	Secondary

End point timeframe:

weeks 116, 128, 140, 156, 180, 208, 232 and 260

End point values	Secukinumab 75mg	Secukinumab 150mg	Placebo - AIN457A 75mg	Placebo - AIN457 150mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	147	161	74	75
Units: percentage of participants				
number (confidence interval 95%)				
week 116	52.4 (44.0 to 60.7)	50.3 (42.2 to 58.5)	47.9 (36.0 to 60.0)	45.8 (34.2 to 57.9)
week 128	54.6 (46.0 to 62.9)	49.4 (41.3 to 57.4)	55.1 (42.7 to 66.9)	57.1 (44.8 to 68.7)
week 140	58.6 (49.9 to 66.7)	46.7 (38.5 to 55.0)	55.6 (43.4 to 67.1)	51.4 (39.4 to 63.2)
week 156	48.6 (40.2 to 57.1)	52.6 (44.4 to 60.6)	43.8 (32.4 to 55.9)	46.6 (35.0 to 58.6)
week 180	54.7 (46.0 to 63.1)	53.3 (44.6 to 61.8)	49.3 (37.0 to 61.6)	58.6 (46.2 to 70.0)
week 208	56.5 (47.8 to 64.8)	52.1 (43.7 to 60.3)	55.2 (42.6 to 67.2)	53.0 (40.4 to 65.3)
week 232	64.3 (55.4 to 72.4)	61.4 (52.5 to 69.6)	65.1 (51.9 to 76.4)	69.5 (56.0 to 80.5)
week 260	55.0 (46.0 to 63.7)	58.3 (49.4 to 66.7)	64.6 (51.7 to 75.8)	66.1 (52.9 to 77.4)

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information	
Timeframe for reporting adverse events: Adverse Events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All Adverse events are reported in this record from First Patient First Treatment until Last Patient Last Visit.	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	20.1

Reporting groups	
Reporting group title	Any AIN457 150 mg
Reporting group description: Any AIN457 150 mg	
Reporting group title	Any AIN457 75 mg
Reporting group description: Any AIN457 75 mg	
Reporting group title	Any AIN457 300 mg
Reporting group description: Any AIN457 300 mg	
Reporting group title	Placebo
Reporting group description: Placebo	

Serious adverse events	Any AIN457 150 mg	Any AIN457 75 mg	Any AIN457 300 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	97 / 473 (20.51%)	48 / 292 (16.44%)	10 / 165 (6.06%)
number of deaths (all causes)	3	3	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	1 / 473 (0.21%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Brain neoplasm			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast cancer			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemangioma			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intraductal papilloma of breast			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intraductal proliferative breast lesion			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Invasive breast carcinoma			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Laryngeal cancer stage 0			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metastases to bone			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-small cell lung cancer			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian germ cell teratoma benign			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Phaeochromocytoma			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleomorphic adenoma			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	2 / 473 (0.42%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Schwannoma			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma of pharynx			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Uterine leiomyoma			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Aortic aneurysm			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Deep vein thrombosis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertension			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive crisis			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic venous thrombosis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Polyarteritis nodosa			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion spontaneous			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Impaired healing			
subjects affected / exposed	2 / 473 (0.42%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Non-cardiac chest pain			
subjects affected / exposed	4 / 473 (0.85%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral swelling			
subjects affected / exposed	1 / 473 (0.21%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Adenomyosis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Adnexa uteri cyst			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endometriosis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Menorrhagia			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metrorrhagia			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pelvic adhesions			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine haemorrhage			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Haemothorax			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary alveolar haemorrhage			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	3 / 473 (0.63%)	0 / 292 (0.00%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 3	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Cervical vertebral fracture			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Comminuted fracture			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eyelid injury			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Face injury			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Facial bones fracture			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fall			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femur fracture			
subjects affected / exposed	1 / 473 (0.21%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fibula fracture			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head injury			

subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meniscus injury			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic fracture			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Periprosthetic osteolysis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rib fracture			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin abrasion			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sternal fracture			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subarachnoid haemorrhage			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	1 / 473 (0.21%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Traumatic liver injury			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ulna fracture			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			

subjects affected / exposed	2 / 473 (0.42%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 5	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Angina pectoris			
subjects affected / exposed	2 / 473 (0.42%)	2 / 292 (0.68%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Angina unstable			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arrhythmia			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	1 / 473 (0.21%)	4 / 292 (1.37%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 6	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrioventricular block second degree			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	2 / 473 (0.42%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	2 / 473 (0.42%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery disease			

subjects affected / exposed	2 / 473 (0.42%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Coronary artery insufficiency			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 473 (0.00%)	3 / 292 (1.03%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Myocarditis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Palpitations			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinus node dysfunction			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ventricular tachycardia			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Cerebral infarction			

subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Encephalopathy			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hemiplegia			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Intracranial venous sinus thrombosis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ischaemic stroke			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Presyncope			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombotic stroke			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Transient ischaemic attack			
subjects affected / exposed	1 / 473 (0.21%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Haemolytic anaemia			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukocytosis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Normocytic anaemia			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Vertigo positional			
subjects affected / exposed	0 / 473 (0.00%)	2 / 292 (0.68%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Ocular myasthenia			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	1 / 473 (0.21%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain			
subjects affected / exposed	2 / 473 (0.42%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	2 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aphthous ulcer			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ischaemic			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis ulcerative			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Crohn's disease			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea haemorrhagic			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysphagia			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Enteritis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Femoral hernia			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric haemorrhage			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ileus			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	2 / 473 (0.42%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Large intestine polyp			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mouth ulceration			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Obstructive pancreatitis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Odynophagia			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rectal haemorrhage			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Biliary colic			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis			
subjects affected / exposed	2 / 473 (0.42%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholecystitis acute			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic hepatitis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug-induced liver injury			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Erythema nodosum			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rosacea			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 473 (0.21%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nephrolithiasis			
subjects affected / exposed	2 / 473 (0.42%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureterolithiasis			
subjects affected / exposed	2 / 473 (0.42%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Basedow's disease			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Goitre			
subjects affected / exposed	0 / 473 (0.00%)	2 / 292 (0.68%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arthritis			
subjects affected / exposed	2 / 473 (0.42%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Back pain			
subjects affected / exposed	3 / 473 (0.63%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 4	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foot deformity			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc degeneration			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral disc protrusion			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Limb asymmetry			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lumbar spinal stenosis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	7 / 473 (1.48%)	3 / 292 (1.03%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 9	0 / 3	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteochondrosis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain in extremity			

subjects affected / exposed	2 / 473 (0.42%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 2	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psoriatic arthropathy			
subjects affected / exposed	5 / 473 (1.06%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 6	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rotator cuff syndrome			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Scoliosis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovitis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Abdominal sepsis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abscess limb			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendiceal abscess			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Appendicitis			

subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	4 / 473 (0.85%)	2 / 292 (0.68%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	3 / 4	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dengue fever			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea infectious			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	3 / 473 (0.63%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 4	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Erysipelas			
subjects affected / exposed	1 / 473 (0.21%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia sepsis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia urinary tract infection			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intervertebral discitis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Klebsiella sepsis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung abscess			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Necrotising fasciitis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	4 / 473 (0.85%)	3 / 292 (1.03%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	3 / 4	3 / 3	1 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Post procedural infection			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostatitis Escherichia coli			

subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash pustular			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salpingo-oophoritis			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 473 (0.00%)	2 / 292 (0.68%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	1 / 473 (0.21%)	2 / 292 (0.68%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	2 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 473 (0.00%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Streptococcal infection			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tonsillitis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Typhoid fever			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	2 / 473 (0.42%)	1 / 292 (0.34%)	1 / 165 (0.61%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection bacterial			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urosepsis			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Viral infection			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound infection staphylococcal			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 473 (0.00%)	1 / 292 (0.34%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			

subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	1 / 473 (0.21%)	0 / 292 (0.00%)	0 / 165 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo		
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 202 (5.45%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Brain neoplasm			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Breast cancer			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haemangioma			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intraductal papilloma of breast			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Intraductal proliferative breast lesion				
subjects affected / exposed	1 / 202 (0.50%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Invasive breast carcinoma				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Laryngeal cancer stage 0				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Leiomyosarcoma				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metastases to bone				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-small cell lung cancer				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ovarian germ cell teratoma benign				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Phaeochromocytoma				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleomorphic adenoma				

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Prostate cancer				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Schwannoma				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Squamous cell carcinoma of pharynx				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Uterine leiomyoma				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular disorders				
Aortic aneurysm				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Deep vein thrombosis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertension				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypertensive crisis				

subjects affected / exposed	1 / 202 (0.50%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pelvic venous thrombosis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Polyarteritis nodosa				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pregnancy, puerperium and perinatal conditions				
Abortion spontaneous				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
General disorders and administration site conditions				
Impaired healing				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Non-cardiac chest pain				
subjects affected / exposed	1 / 202 (0.50%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Peripheral swelling				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyrexia				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Reproductive system and breast disorders			
Adenomyosis			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Adnexa uteri cyst			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endometriosis			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Menorrhagia			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metrorrhagia			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic adhesions			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Uterine haemorrhage			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Haemothorax			

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pleural effusion				
subjects affected / exposed	1 / 202 (0.50%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Pulmonary alveolar haemorrhage				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pulmonary embolism				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Psychiatric disorders				
Depression				
subjects affected / exposed	1 / 202 (0.50%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Injury, poisoning and procedural complications				
Cervical vertebral fracture				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Comminuted fracture				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Eyelid injury				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Face injury			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Facial bones fracture			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fall			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Femur fracture			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fibula fracture			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Head injury			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Meniscus injury			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Multiple injuries			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pelvic fracture			

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Periprosthetic osteolysis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rib fracture				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skin abrasion				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skull fracture				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sternal fracture				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Subarachnoid haemorrhage				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thoracic vertebral fracture				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tibia fracture				

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Toxicity to various agents				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Traumatic liver injury				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ulna fracture				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Wound dehiscence				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac disorders				
Acute myocardial infarction				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Angina pectoris				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Angina unstable				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Arrhythmia				

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrial fibrillation				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atrioventricular block second degree				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac failure				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cardiac failure congestive				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Coronary artery disease				
subjects affected / exposed	1 / 202 (0.50%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Coronary artery insufficiency				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myocardial infarction				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myocarditis				

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Palpitations				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sinus node dysfunction				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ventricular tachycardia				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nervous system disorders				
Cerebral haemorrhage				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebral infarction				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebrovascular accident				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dizziness				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Encephalopathy				

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hemiplegia				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intracranial venous sinus thrombosis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ischaemic stroke				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Presyncope				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Syncope				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thrombotic stroke				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Transient ischaemic attack				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood and lymphatic system disorders				
Haemolytic anaemia				

subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leukocytosis			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Normocytic anaemia			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ear and labyrinth disorders			
Vertigo positional			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Ocular myasthenia			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal adhesions			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal pain			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aphthous ulcer			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Colitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colitis ischaemic				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Colitis ulcerative				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Crohn's disease				
subjects affected / exposed	1 / 202 (0.50%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Diarrhoea haemorrhagic				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dysphagia				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Enteritis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Femoral hernia				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastric haemorrhage				

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal haemorrhage				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Haemorrhoids				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ileus				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Inguinal hernia				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Large intestine polyp				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Mouth ulceration				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Obstructive pancreatitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Odynophagia				

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophagitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rectal haemorrhage				
subjects affected / exposed	1 / 202 (0.50%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Small intestinal obstruction				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Umbilical hernia				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatobiliary disorders				
Biliary colic				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cholecystitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cholecystitis acute				

subjects affected / exposed	1 / 202 (0.50%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Cholelithiasis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic hepatitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Drug-induced liver injury				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skin and subcutaneous tissue disorders				
Erythema nodosum				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rosacea				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Renal and urinary disorders				
Acute kidney injury				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nephrolithiasis				
subjects affected / exposed	1 / 202 (0.50%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Ureterolithiasis				

subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Basedow's disease			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Goitre			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arthritis			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Back pain			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Foot deformity			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Intervertebral disc degeneration			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Intervertebral disc protrusion			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Limb asymmetry			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lumbar spinal stenosis			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis			
subjects affected / exposed	1 / 202 (0.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Osteochondrosis			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pain in extremity			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psoriatic arthropathy			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Rotator cuff syndrome			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Scoliosis			

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Synovitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
Abdominal sepsis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Abscess limb				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Appendiceal abscess				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Appendicitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dengue fever				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diarrhoea infectious				

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Erysipelas				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia sepsis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia urinary tract infection				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Intervertebral discitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Klebsiella sepsis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Lung abscess				

subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Necrotising fasciitis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophageal candidiasis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Post procedural infection				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Prostatitis Escherichia coli				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Rash pustular				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Salpingo-oophoritis				
subjects affected / exposed	0 / 202 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				

subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Septic shock			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sinusitis			
subjects affected / exposed	1 / 202 (0.50%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Streptococcal infection			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Tonsillitis			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Typhoid fever			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection bacterial			

subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urosepsis			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Viral infection			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound infection staphylococcal			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Any AIN457 150 mg	Any AIN457 75 mg	Any AIN457 300 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	264 / 473 (55.81%)	197 / 292 (67.47%)	47 / 165 (28.48%)
Vascular disorders			
Hypertension			
subjects affected / exposed	33 / 473 (6.98%)	27 / 292 (9.25%)	7 / 165 (4.24%)
occurrences (all)	33	28	9
Nervous system disorders			
Headache			
subjects affected / exposed	42 / 473 (8.88%)	31 / 292 (10.62%)	1 / 165 (0.61%)
occurrences (all)	67	52	1
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	38 / 473 (8.03%)	23 / 292 (7.88%)	1 / 165 (0.61%)
occurrences (all)	56	36	1
Nausea			
subjects affected / exposed	14 / 473 (2.96%)	17 / 292 (5.82%)	3 / 165 (1.82%)
occurrences (all)	16	20	3
Vomiting			
subjects affected / exposed	8 / 473 (1.69%)	15 / 292 (5.14%)	0 / 165 (0.00%)
occurrences (all)	11	19	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	30 / 473 (6.34%)	21 / 292 (7.19%)	3 / 165 (1.82%)
occurrences (all)	44	24	4
Oropharyngeal pain			
subjects affected / exposed	19 / 473 (4.02%)	20 / 292 (6.85%)	1 / 165 (0.61%)
occurrences (all)	27	28	1
Skin and subcutaneous tissue disorders			
Psoriasis			
subjects affected / exposed	23 / 473 (4.86%)	23 / 292 (7.88%)	2 / 165 (1.21%)
occurrences (all)	24	24	2
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	30 / 473 (6.34%)	24 / 292 (8.22%)	3 / 165 (1.82%)
occurrences (all)	41	38	4
Back pain			

subjects affected / exposed	33 / 473 (6.98%)	30 / 292 (10.27%)	3 / 165 (1.82%)
occurrences (all)	40	39	3
Psoriatic arthropathy			
subjects affected / exposed	27 / 473 (5.71%)	23 / 292 (7.88%)	2 / 165 (1.21%)
occurrences (all)	32	26	2
Infections and infestations			
Bronchitis			
subjects affected / exposed	35 / 473 (7.40%)	24 / 292 (8.22%)	9 / 165 (5.45%)
occurrences (all)	53	29	10
Gastroenteritis			
subjects affected / exposed	30 / 473 (6.34%)	10 / 292 (3.42%)	2 / 165 (1.21%)
occurrences (all)	46	15	2
Nasopharyngitis			
subjects affected / exposed	101 / 473 (21.35%)	70 / 292 (23.97%)	14 / 165 (8.48%)
occurrences (all)	220	138	14
Pharyngitis			
subjects affected / exposed	22 / 473 (4.65%)	15 / 292 (5.14%)	0 / 165 (0.00%)
occurrences (all)	34	21	0
Sinusitis			
subjects affected / exposed	26 / 473 (5.50%)	17 / 292 (5.82%)	3 / 165 (1.82%)
occurrences (all)	34	29	4
Upper respiratory tract infection			
subjects affected / exposed	91 / 473 (19.24%)	62 / 292 (21.23%)	10 / 165 (6.06%)
occurrences (all)	153	98	17
Urinary tract infection			
subjects affected / exposed	27 / 473 (5.71%)	21 / 292 (7.19%)	2 / 165 (1.21%)
occurrences (all)	40	27	2

Non-serious adverse events	Placebo		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	63 / 202 (31.19%)		
Vascular disorders			
Hypertension			
subjects affected / exposed	5 / 202 (2.48%)		
occurrences (all)	6		
Nervous system disorders			

Headache subjects affected / exposed occurrences (all)	7 / 202 (3.47%) 8		
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Vomiting subjects affected / exposed occurrences (all)	 6 / 202 (2.97%) 7 2 / 202 (0.99%) 2 1 / 202 (0.50%) 1		
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all) Oropharyngeal pain subjects affected / exposed occurrences (all)	 6 / 202 (2.97%) 9 4 / 202 (1.98%) 5		
Skin and subcutaneous tissue disorders Psoriasis subjects affected / exposed occurrences (all)	 1 / 202 (0.50%) 1		
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all) Back pain subjects affected / exposed occurrences (all) Psoriatic arthropathy subjects affected / exposed occurrences (all)	 3 / 202 (1.49%) 3 2 / 202 (0.99%) 2 2 / 202 (0.99%) 2		
Infections and infestations			

Bronchitis			
subjects affected / exposed	6 / 202 (2.97%)		
occurrences (all)	7		
Gastroenteritis			
subjects affected / exposed	2 / 202 (0.99%)		
occurrences (all)	2		
Nasopharyngitis			
subjects affected / exposed	11 / 202 (5.45%)		
occurrences (all)	12		
Pharyngitis			
subjects affected / exposed	0 / 202 (0.00%)		
occurrences (all)	0		
Sinusitis			
subjects affected / exposed	4 / 202 (1.98%)		
occurrences (all)	4		
Upper respiratory tract infection			
subjects affected / exposed	12 / 202 (5.94%)		
occurrences (all)	13		
Urinary tract infection			
subjects affected / exposed	2 / 202 (0.99%)		
occurrences (all)	2		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Observed data is reported for outcome measures

The non-fatal adverse events are reported under "Serious Adverse Events"

Notes: